Phthalic Acid

Phthalic Acid

SCHEMBL321766

CCOC(C)OCC.O=C(O)c1ccccc1C(=O)O

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 3/20 0.47
LMNA P02545 2/20 0.46
KDM4E B2RXH2 4/20 0.46
MEN1 O00255 1/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
POLB P06746 2/20 0.45
TDP1 Q9NUW8 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
AKR1C3 P42330 1/20 0.44
ESR1 P03372 1/20 0.43
ITGB3 P05106 1/20 0.43
ITGA2B P08514 1/20 0.43
HMGB1 P09429 1/20 0.43
GGT1 P19440 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phthalic Acid SCHEMBL2420682 0.96 ALDH1A1 (0.50) ALDH1A1ALOX15TSHRLMNAKDM4E
Salicylic Acid SCHEMBL2882428 0.90 ALDH1A1 (0.60) ALDH1A1ALOX15TSHRLMNAKDM4E
Salicylic Acid SCHEMBL4624747 0.88 KDM4E (0.58) ALDH1A1ALOX15TSHRLMNAKDM4E
SCHEMBL6903418 0.88 ALDH1A1 (0.57) ALDH1A1ALOX15TSHRLMNAKDM4E
SCHEMBL7568179 0.85 MEN1 (0.43) ALDH1A1ALOX15TSHRLMNAKDM4E
Formaldehyde SCHEMBL1582461 0.84 KDM4E (0.47) ALDH1A1ALOX15TSHRLMNAKDM4E
Benzil SCHEMBL1923895 0.81 CES2 (0.54) ALDH1A1LMNAMEN1KMT2AMAPT
Quinolinic Acid SCHEMBL8549189 0.81 KDM4E (0.65) ALDH1A1ALOX15TSHRLMNAKDM4E
Phthalic Acid SCHEMBL28522002 0.80 ALDH1A1 (0.48) ALDH1A1ALOX15TSHRLMNAKDM4E
SCHEMBL6469723 0.80 ALDH1A1 (0.44) ALDH1A1ALOX15TSHRLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113645962-A Enteric coated tablet containing dimethyl fumarate 库拉科有限公司 2021-11-12 CN claimed
WO-2020242132-A1 ENTERIC TABLET CONTAINING DIMETHYL FUMARATE 주식회사 큐라클 2020-12-03 WO claimed
WO-2019013403-A1 AGENTS FOR PREVENTING OR TREATING URINARY DISEASE AND PREPARING THE SAME DONGKOO BIO & PHARMA CO., LTD. (KR) 2019-01-17 WO claimed
EP-2457580-A1 Absorption enhancers for drug administration The UAB Research Foundation (US) 2012-05-30 EP claimed
EP-1789075-A4 ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION UAB RESEARCH FOUNDATION (US) 2009-07-01 EP claimed
EP-1789075-A2 ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION THE UAB RESEARCH FOUNDATION (US) 2007-05-30 EP claimed
WO-2006025882-A2 ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION THE UAB RESEARCH FOUNDATION (US) 2006-03-09 WO claimed
US-20060045868-A1 Absorption enhancers for drug administration AEGIS THERAPEUTICS LLC 2006-03-02 US claimed
US-20060045869-A1 Absorption enhancers for drug administration AEGIS THERAPEUTICS LLC 2006-03-02 US claimed
EP-0754452-B1 Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract TANABE SEIYAKU CO (JP) 2002-10-02 EP claimed
US-6309666-B1 HARD CAPSULE CONTAINING ACIDIC SUBSTANCE TO CONTROL RELEASE, POLYMER FILM SOLUBLE AT LOW PH, ENTERIC COATING FILM TANABE SEIYAKU CO., LTD. (JP) 2001-10-30 US claimed
EP-0754452-A2 Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract TANABE SEIYAKU CO., LTD. (JP) 1997-01-22 EP claimed
US-12043674-B2 Synthetic cyclic peptides and methods of preparation and use thereof AUBURN UNIVERSITY (US) 2024-07-23 US disclosed
US-20240189240-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN MAPLIGHT THERAPEUTICS, INC. 2024-06-13 US disclosed
US-20240180841-A1 ENTERIC TABLET CONTAINING DIMETHYL FUMARATE CURACLE CO., LTD. (KR) 2024-06-06 US disclosed
WO-2024076979-A1 CELLULOSE NANOFIBER-BASED COMPOSITIONS FOR EHNANCED FILTRATION EFFICIENCY AND METHODS OF USE THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-11 WO disclosed
US-4933182-A Pharmaceutical composition for treating periodontal ROHTO PHARMACEUTICAL CO. LTD. (JP) 1990-06-12 US disclosed
EP-0241178-A1 Pharmaceutical composition for treating periodontal diseases ROHTO PHARMACEUTICAL CO., LTD. (JP) 1987-10-14 EP disclosed
EP-0241179-A1 Pharmaceutical composition for periodontal diseases ROHTO PHARMACEUTICAL CO., LTD. (JP) 1987-10-14 EP disclosed
US-4041002-A A POLYACETAL, A LUBRICANT, AND AN ETHYLENE-VINYL ACETATE COPOLYMER; WEAR RESISTANT ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) 1977-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180841-A1 ENTERIC TABLET CONTAINING DIMETHYL FUMARATE SI, FH, SLC10A2 ALDH1A1 3022/4885ALOX15 3229/4885TSHR 4434/4885
US-12043674-B2 Synthetic cyclic peptides and methods of preparation and use thereof VIP, PTMS, IAPP ALDH1A1 4861/4885ALOX15 3887/4885TSHR 2949/4885
US-20240189240-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING ZOLMITRIPTAN HTR3A, HTR5A, GRIN3A ALDH1A1 3176/4885ALOX15 597/4885TSHR 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.